Insider Screener
Real-time Form 4 Filtering Engine
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry (by SEC) | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-24 00:19 | 2025-01-21 | PHAT | Phathom Pharmaceuticals, Inc. | Curran Terrie | Director, Officer; President and Chief Executive | Pharmaceutical Preparations | SALE | $6.59 | 19,109 | $125,884 | 360,465 | -5.0% |
| 2024-11-14 02:45 | 2024-11-11 | ARQT | Arcutis Biotherapeutics Inc. | Curran Terrie | Director | Pharmaceutical Preparations | SALE | $10.85 | 8,687 | $94,238 | 10,139 | -46.1% |
| 2024-07-17 21:50 | 2024-07-15 | PHAT | Phathom Pharmaceuticals, Inc. | Curran Terrie | Director, Officer; President and Chief Executive | Pharmaceutical Preparations | SALE | $11.72 | 33,848 | $396,699 | 377,734 | -8.2% |
| 2024-03-26 23:05 | 2024-03-22 | PHAT | Phathom Pharmaceuticals, Inc. | Curran Terrie | Director, Officer; President and Chief Executive | Pharmaceutical Preparations | SALE | $9.11 | 16,851 | $153,513 | 410,784 | -3.9% |
| 2023-04-07 22:19 | 2023-04-06 | PHAT | Phathom Pharmaceuticals, Inc. | Curran Terrie | Director, Officer; President and Chief Executive | Pharmaceutical Preparations | BUY | $7.82 | 12,919 | $101,025 | 188,290 | +7.4% |
| 2023-03-04 02:59 | 2023-03-01 | PHAT | Phathom Pharmaceuticals, Inc. | Curran Terrie | Director, Officer; President and Chief Executive | Pharmaceutical Preparations | SALE | $8.54 | 1,436 | $12,265 | 175,371 | -0.8% |
| 2023-01-21 03:39 | 2023-01-20 | PHAT | Phathom Pharmaceuticals, Inc. | Curran Terrie | Director, Officer; President and Chief Executive | Pharmaceutical Preparations | SALE | $8.20 | 5,821 | $47,729 | 176,807 | -3.2% |
| 2022-11-24 00:07 | 2022-11-21 | PHAT | Phathom Pharmaceuticals, Inc. | Curran Terrie | Director, Officer; President and Chief Executive | Pharmaceutical Preparations | SALE | $9.60 | 1,526 | $14,650 | 83,720 | -1.8% |
| 2022-05-17 03:45 | 2022-05-13 | PHAT | Phathom Pharmaceuticals, Inc. | Curran Terrie | Director, Officer; President and Chief Executive | Pharmaceutical Preparations | BUY | $7.41 | 20,500 | $151,835 | 64,595 | +46.5% |
| 2021-09-13 23:11 | 2021-09-09 | MYOV | Myovant Sciences Ltd. | Curran Terrie | Director | Pharmaceutical Preparations | OPT+S | $25.58 | 4,850 | $124,063 | 0 | -100.0% |
| 2021-09-03 23:25 | 2021-09-01 | MYOV | Myovant Sciences Ltd. | Curran Terrie | Director | Pharmaceutical Preparations | OPT+S | $25.02 | 48,508 | $1,213,816 | 0 | -100.0% |
| 2021-03-24 02:22 | 2021-03-22 | PHAT | Phathom Pharmaceuticals, Inc. | Curran Terrie | Director, Officer; President and Chief Executive | Pharmaceutical Preparations | OPT+S | $43.32 | 11,513 | $498,751 | 0 | -100.0% |
| 2019-09-19 23:05 | 2019-09-18 | CELG | N/A | Curran Terrie | Officer; SEE REMARKS | Other | OPT+S | $98.27 | 11,338 | $1,114,143 | 2,155 | -84.0% |
| 2017-09-26 23:29 | 2017-09-25 | CELG | N/A | Curran Terrie | Officer; See remarks | Other | SALE | $143.89 | 1,727 | $248,498 | 3,925 | -30.6% |
Strategic Signal Filtering
Our screener allows you to cut through the noise of routine stock grants and small trades. By focusing on high-value transactions from C-suite executives (CEO/CFO), you can identify where the "Smart Money" is being deployed with maximum conviction.
Investing Without Illusions
Insider data is not a magic wand, but it is the most honest indicator available. While insiders sell for many reasons (taxes, personal needs), they generally buy for only one: they believe the stock price is undervalued. We provide the tools to track these skin-in-the-game moves.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.